Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II)
www.thelancet.com/journals/lan...
FASTRACK II, the first phase 2 trial of stereotactic ablative body radiotherapy☢️ in #KidneyCancer #ESTRO26